Sagimet Biosciences Inc.

10/29/2024 | Press release | Distributed by Public on 10/29/2024 05:09

Sagimet Biosciences Announces Successful Completion of End of Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by[...]

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.